Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

Radial Access Best for PCI Following Thrombolysis in STEMI

News Daily News

Radial Access Best for PCI Following Thrombolysis in STEMI

Michael O'Riordan

November 27, 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

November 14, 2017

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

News Conference News AHA 2017

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

Michael O'Riordan

November 12, 2017

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

News Daily News

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

September 22, 2017

Stable Angina: PCI vs CABG vs OMT

Presentation iASSESS 2017

Stable Angina: PCI vs CABG vs OMT

Presenter: Robert T. Pyo

August 30, 2017

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

May 23, 2017

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

News Daily News

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

April 24, 2017

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

News Conference News ACC 2017

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

Yael L. Maxwell

March 19, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Meta-analysis Calls Into Question Strength of Guidance for RAS Blockade in Patients With Stable CAD

January 19, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.